X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CER-001 is a novel engineered HDL-mimetic comprised of recombinant human apoA-I and phospholipids, designed to mimic the beneficial properties of nascent pre-β HDL. It is being investigated for the treatment of septic patients at high risk of developing acute kidney injury.
Lead Product(s): CER-001
Therapeutic Area: Infections and Infectious Diseases Product Name: CER-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2023
Details:
The results to date with CER-001 are consistent with the known pleiotropic effects of HDL, scavenging endotoxin, reversing the cytokine cascade and improving endothelial function.
Lead Product(s): Human recombinant apoA-I,Sphingomyelins,Dipalmitoylphosphatidylglycerol
Therapeutic Area: Nephrology Product Name: CER-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
CER-001 is the first-in-class bio-HDL mimetic that directly targets a key underlying metabolic defect of LCAT deficiency. The bio-HDL is one of the most advanced biomedicines and is a potential novel treatment for kidney diseases.
Lead Product(s): Human Recombinant ApoA-I,Sphingomyelins,Dipalmitoylphosphatidylglycerol
Therapeutic Area: Rare Diseases and Disorders Product Name: CER-001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2022
Details:
ABIONYX has received authorization to launch a clinical RACERS trial (a RAndomized study comparing short-term CER-001 infusions at different doses to prevent Sepsis-induced acute kidney injury) with CER-001 in septic patients at high risk of developing acute kidney injury.
Lead Product(s): Human recombinant apoA-I,Sphingomyelins,Dipalmitoylphosphatidylglycerol
Therapeutic Area: Nephrology Product Name: CER-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
